1. Stem Cell/Wnt PI3K/Akt/mTOR Apoptosis
  2. Organoid Akt Apoptosis
  3. Ipatasertib tosylate

Ipatasertib tosylate  (Synonyms: GDC-0068 tosylate; RG7440 tosylate)

目录号: HY-15186C
产品使用指南

Ipatasertib (GDC-0068) tosylate 是一种口服有效的、高选择性和 ATP 竞争性泛 Akt 抑制剂,其对 Akt1/2/3IC50 值分别为 5、18、8 nM。Ipatasertib 通过抑制 Akt 导致非 p53 依赖性的 PUMA 激活,从而同步激活 FoxO3a 和 NF-κB 。Ipatasertib 还能诱导癌细胞凋亡 (apoptosis),抑制异种移植小鼠模型中的肿瘤生长。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Ipatasertib tosylate Chemical Structure

Ipatasertib tosylate Chemical Structure

CAS No. : 1491138-24-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Ipatasertib tosylate 的其他形式现货产品:

Customer Review

Other Forms of Ipatasertib tosylate:

MCE 顾客使用本产品发表的 39 篇科研文献

WB

    Ipatasertib tosylate purchased from MCE. Usage Cited in: Front Oncol. 2021 Nov 24:11:766298.  [Abstract]

    Ipatasertib (0.625, 1.25, 5 µM; 24 h) increases the phosphorylation of AKT in MFM-223 FGFR2amp cells.

    Ipatasertib tosylate purchased from MCE. Usage Cited in: Skelet Muscle. 2021 Mar 15;11(1):6.  [Abstract]

    The western blot analysis and quantification of phosphorylated and all forms of AKT and P70, MyoG, and MyoD, after transfecting miR-1290/miR-NC with or without GDC0068. GDC-0068 inhibits miR-1290-activated phosphorylation of AKT and P70 in C2C12 myoblasts.

    Ipatasertib tosylate purchased from MCE. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145.  [Abstract]

    C2C12 myoblasts were pre-incubated with 2.5 μM GDC-0068 for 30 min then treated with 0.2 μM S-Rg3. After incubation with S-Rg3 for 72 h and 24 h, Western blotting is used to detect levels of Myf5 and myogenin in C2C12 myoblasts after incubation of cells with S-Rg3 for 120 h. GDC-0068 inhibits S-Rg3-activated phosphorylation of Akt and mTOR in C2C12 myoblasts.

    查看 Akt 亚型特异性产品:

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2].

    IC50 & Target

    Akt1

    5 nM (IC50)

    Akt2

    18 nM (IC50)

    Akt3

    8 nM (IC50)

    PKA

    3100 nM (IC50)

    体外研究
    (In Vitro)

    Ipatasertib tosylate (10 µM; 12, 24 h) 在细胞实验中,通过非 p53 依赖性的 PUMA 激活抑制结肠癌细胞增殖[1]
    Ipatasertib tosylate (1, 5, 10, 20 μM; 24 h/10 μM; 3, 6, 12, 24 h) 在 HCT116 细胞中,以时间和浓度依赖的方式上调 PUMA 的表达[1]
    Ipatasertib tosylate 在野生型、p53−/− 型, 以及 DLD1 (p53 突变) 型 HCT116 细胞中增加 PUMA 的 mRNA 水平[1]
    Ipatasertib tosylate (10 µM; 24 h) 通过 PUMA/Bax 途径诱导 HCT116 细胞凋亡[1]
    Cell Viability Assay:[1]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: HCT116 WT, p53−/−, and DLD1 (p53 mutant) cells
    Concentration: 10 µM
    Incubation Time: 12, 24 h
    Result: Decreased all the three cell lines viability.

    Apoptosis Analysis[1]

    Cell Line: HCT116 cells
    Concentration: 10 µM
    Incubation Time: 24 h
    Result: Induced apoptosis through PUMA/Bax pathway.

    Western Blot Analysis[1]

    Cell Line: HCT116 WT, p53−/−, and DLD1 (p53 mutant) cells
    Concentration: 1, 5, 10, 20 μM for 24 h/10 μM for 3, 6, 12, 24 h
    Incubation Time: 24 h; 3, 6, 12, 24 h
    Result: Increased the level of PUMA in a concentration and time dependent manner.
    体内研究
    (In Vivo)

    Ipatasertib tosylate (30 mg/kg; p.o.; single daily for 15 consecutive days) 在野生型和 PUMA−/− 型 HCT116 异种移植小鼠模型中显示出 PUMA 依赖性抗肿瘤活性[1]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: HCT116 WT and PUMA−/− cells xenograft nude mice model[1].
    Dosage: 30 mg/kg
    Administration: Oral gavage; single daily for 15 consecutive days.
    Result: Inhibited growth of tumors in a PUMA-dependent manner.
    分子量

    630.20

    Formula

    C31H40ClN5O5S

    CAS 号
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    纯度 & 产品资料
    参考文献
    • 摩尔计算器

    • 稀释计算器

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量   浓度   体积   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Ipatasertib tosylate
    目录号:
    HY-15186C
    需求量: